This study questioned whether US state cannabis legalisation or commercialisation was associated with increased rates of psychosis-related healthcare claims. In this cohort study of claims data from beneficiaries between 2003 and 2017, there was no statistically significant difference in the rates of psychosis-related diagnoses or prescribed antipsychotics in states with medical or recreational cannabis policies compared with states with no such policy. The findings of this study do not support an association between state policies legalising cannabis and psychosis-related outcomes.
Read more ... State Cannabis Legalisation and Psychosis-Related Health Care Utilisation